The Alpha Emitter Astatine-211 Targeted to CD38 Can Eradicate Multiple Myeloma in Minimal Residual Disease Models

ConclusionsThe efficacy of CD38 targeted 211At appears to be a function of disease distribution and malignant plasma cell access, as compellingly demonstrated by our models. Bulky tumor geometry reduces mAb penetration. In contrast, the isolated cells and small tumor clusters that define MRD are readily accessible to mAbs, creating optimal conditions for α-emitter cell kill. In an era of highly potent MM therapy, preventing relapse remains frustratingly rare. Our approach is both agnostic to high-risk cytogenetic features and offers the potential to eliminate all residual MM cell clones. These encouraging findings will be explored in a clinical trial of 211At-CD38 RIT.DisclosuresOrozco: Actinium Pharmaceuticals: Research Funding. Jones: Juno Therapeutics, a Celgene Company: Employment, Equity Ownership. Till: Mustang Bio: Patents & Royalties, Research Funding. Gopal: Teva: Research Funding; Spectrum: Research Funding; Janssen: Consultancy, Research Funding; BMS: Research Funding; Incyte: Consultancy; Gilead: Consultancy, Research Funding; Seattle Genetics: Consultancy, Research Funding; Brim: Consultancy; Pfizer: Research Funding; Aptevo: Consultancy; Takeda: Research Funding; Merck: Research Funding; Asana: Consultancy. Green: Juno Therapeutics: Patents & Royalties, Research Funding.

Source: Blood - November 21, 2018 Category: Hematology Authors: O'Steen, S., Comstock, M. C., Orozco, J. J., Hamlin, D. K., Wilbur, D. S., Jones, J., Kenoyer, A., Nartea, M. E., Lin, Y., Miller, B. W., Tuazon, S. A., Till, B. G., Gopal, A. K., Sandmaier, B. M., Press, O. W., Green, D. J. Tags: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster I Source Type: research